Association of Circulating Osteopontin Levels With Lower Extremity Arterial Disease in Subjects With Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study
Restricted accessResearch articleFirst published online June, 2020
Association of Circulating Osteopontin Levels With Lower Extremity Arterial Disease in Subjects With Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study
Osteopontin (OPN) is involved in the atherosclerotic and inflammatory process. In this article, we examined the relationship between circulating OPN levels with lower extremity arterial disease (LEAD) in individuals with type 2 diabetes mellitus (T2DM). Seventy individuals with T2DM and 66 individuals without T2DM were recruited. Diagnosis of LEAD was based on the absence of triphasic waveform on the pedal arteries. Plasma OPN levels were determined by Luminex Multiplex immunoassay. LEAD was present in 34 (48.6%) patients with T2DM. In the diabetes cohort, individuals with LEAD had higher plasma OPN concentrations than those without LEAD (geometric mean [95% confidence intervals]; 43.4 [37.5-50.4] vs 26.1 [22.9-29.8] ng/mL, respectively, P < .001). Multivariable analysis showed that presence of LEAD independently associated with higher OPN levels in subjects with T2DM, with marginal statistical significance (P = .049). In both cohorts, plasma OPN concentrations were negatively associated with ankle-brachial index values (P < .05). In the total sample, there was a gradual increase of OPN levels across subgroups with triphasic, biphasic, and monophasic/blunted waveforms (P < .001). In conclusion, plasma OPN levels are associated with the presence and severity of LEAD in subjects with T2DM. Further studies are needed to investigate the role of OPN in the pathogenesis and progression of LEAD.
O’ReganABermanJS.Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000;81:373-390.
2.
ScatenaMLiawLGiachelliCM.Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302-2309.
3.
O’BrienERGarvinMRStewartDK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb. 1994;14:1648-1656.
4.
TousoulisDSiasosGManiatisK, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013;167:1924-1928.
5.
AbdalrhimADMarroushTSAustinEE, et al. Plasma osteopontin levels and adverse cardiovascular outcomes in the PEACE trial. PLoS One. 2016;11:e0156965.
6.
CarboneFRigamontiFBurgerF, et al. Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. Int J Cardiol. 2018;255:195-199.
7.
YamaguchiHIgarashiMHirataA, et al. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J. 2004;51:499-504.
8.
ZhangXCheeWKLiuS, et al. Association of plasma osteopontin with diabetic retinopathy in Asians with type 2 diabetes. Mol Vis. 2018;24:165-173.
9.
MaserRELenhardMJPohligRTBalagopalPB.Osteopontin and osteoprotegerin levels in type 2 diabetes and their association with cardiovascular autonomic function. J Diabetes Complications. 2016;30:507-510.
10.
ZwakenbergSRvan der SchouwYTSchalkwijkCGSpijkermanAMWBeulensJWJ. Bone markers and cardiovascular risk in type 2 diabetes patients. Cardiovasc Diabetol. 2018;17:45.
11.
WolakT.Osteopontin—a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014;236:327-337.
12.
DinhTScovellSVevesA.Peripheral arterial disease and diabetes: a clinical update. Int J Low Extrem Wounds. 2009;8:75-81.
13.
TziomalosKAthyrosVG.Diabetic nephropathy: new risk factors and improvements in diagnosis. Rev Diabet Stud. 2015;12:110-118.
14.
ChenYWWangYYZhaoD, et al. High prevalence of lower extremity peripheral artery disease in type 2 diabetes patients with proliferative diabetic retinopathy. PLoS One. 2015;10:e0122022.
15.
PirartJ.Diabetic neuropathy: a metabolic or a vascular disease?Diabetes. 1965;14:1-9.
16.
American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;41(suppl 1):S13-S27.
17.
de BoerIHBangaloreSBenetosA, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:1273-1284.
18.
GrossJLde AzevedoMJSilveiroSPCananiLHCaramoriMLZelmanovitzT.Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164-176.
19.
DyckPJ.Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve. 1988;11:21-32.
20.
YoungMJBoultonAJMacLeodAFWilliamsDRSonksenPH.A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150-154.
21.
EwingDJMartynCNYoungRJClarkeBF.The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985;8:491-498.
22.
Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Autonomic nervous system testing. Muscle Nerve. 1992;15:1158-1166.
23.
WilliamsDTHardingKGPriceP.An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes. Diabetes Care. 2005;28:2206-2210.
24.
American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26:3333-3341.
25.
Gómez-AmbrosiJCatalánVRamírezB, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab. 2007;92:3719-3727.
26.
AhmadRAl-MassAAl-GhawasD, et al. Interaction of osteopontin with IL-18 in obese individuals: implications for insulin resistance. PLoS One. 2013;8:e63944.
27.
KahlesFFindeisenHMBruemmerD.Osteopontin: a novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 2014;3:384-393.
28.
KieferFWZeydaMGollingerK, et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes. 2010;59:935-946.
29.
ShammasNW.Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3:229-234.
30.
BrownleeM.The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625.
31.
MohammediKWoodwardMHirakawaY, et al; ADVANCE Collaborative Group. Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes. Diabetes Care. 2016;39:1796-1803.
32.
SelvinEWattanakitKSteffesMWCoreshJSharrettAR.HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2006;29:877-882.
33.
KoshikawaMAizawaKKasaiH, et al. Elevated osteopontin levels in patients with peripheral arterial disease. Angiology. 2009;60:42-45.
34.
HansSMaliAM.Estimation and comparison of osteopontin levels in plasma in subjects with healthy periodontium and generalized chronic periodontitis and its assessment after scaling and root planing. J Indian Soc Periodontol. 2012;16:354-357.
35.
ToossiPAminiSHSAminiMSA, et al. Assessment of serum levels of osteopontin, selenium and prolactin in patients with psoriasis compared with healthy controls, and their association with psoriasis severity. Clin Exp Dermatol. 2015;40:741-746.
36.
SamitasKZervasEVittorakisS, et al. Osteopontin expression and relation to disease severity in human asthma. Eur Respir J. 2011;37:331-341.
37.
SibleyRC3rdReisSPMacFarlaneJJReddickMAKalvaSPSutphinPD.Noninvasive physiologic vascular studies: a guide to diagnosing peripheral arterial disease. Radiographics. 2017;37:346-357.
38.
LundSAGiachelliCMScatenaM.The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009;3:311-322.
39.
ChibaSOkamotoHKonS, et al. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels. 2002;16:111-117.
40.
BruemmerDCollinsARNohG, et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003;112:1318-1331.
41.
Abdel-AzeezHAAl-ZakyM.Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis. J Clin Lab Anal. 2010;24:201-206.
42.
SpeerMYMcKeeMDGuldbergRE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein–deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med. 2002;196:1047-1055.
Álvaro-AfonsoFJLázaro-MartínezJLAragón-SánchezJGarcía-MoralesEGarcía-ÁlvarezYMolines-BarrosoRJ.What is the clinical utility of the ankle-brachial index in patients with diabetic foot ulcers and radiographic arterial calcification?Int J Low Extrem Wounds. 2015;14:372-376.
45.
BerezinAEKremzerAA.Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis. 2013;229:475-481.
46.
NiskanenLKSuhonenMSiitonenOLehtinenJMUusitupaMI.Aortic and lower limb artery calcification in type 2 (non–insulin-dependent) diabetic patients and non-diabetic control subjects. A five year follow-up study. Atherosclerosis. 1990;84:61-71.
47.
FagliaE.Characteristics of peripheral arterial disease and its relevance to the diabetic population. Int J Low Extrem Wounds. 2011;10:152-166.
48.
Gerhard-HermanMDGornikHLBarrettC, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2017;135:e686-e725.
49.
AboyansVRiccoJBBartelinkMEL, et al; ESC Scientific Document Group. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European Stroke Organization (ESO), the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763-816.
